Compare Gilead Sciences, Inc. (GILD) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Upstart Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Upstart Holdings Inc trades at $29.98 (market cap $2.94B). The key difference: Gilead Sciences, Inc. is far larger — about 56.1× Upstart Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| GILD | UPST | |
|---|---|---|
Market Cap | $164.99B | $2.94B |
Sector | Health | Financials |
52-Week High | $155.80 | $73.76 |
52-Week Low | $110.56 | $24.22 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
